Macro Dashboard
| Indicator | Level | 5-Day Δ | Signal |
|---|---|---|---|
| KOSPI | 6,684.4 | −3.9% | Weak |
| KOSDAQ | 806.8 | −0.6% | Flat |
| VIX | 17.6 | +11.8% | Stable |
| US 10Y | 4.97% | +0.19pp | Rising |
| DXY | 99.5 | +0.8% | Firm |
| USD/KRW | 1,346 | +0.2% | Flat |
| Brent | $107.5 | +6.2% | Rising |
Regime: KR Bear / US Neutral. Stance: trim Korea exposure, build cash. KOSPI’s −3.9% five-day loss versus KOSDAQ’s −0.6% reflects large-cap index mechanics rather than a broad collapse — individual-stock breadth above the 50-day MA still holds at 55.5%.
Market Wrap
Source: KR Market Snapshot — same-day DB (Sep 14, 2026). Full close briefing was not available for this session; intraday and flow data are used instead.
Today was a concentrated large-cap unwind, not a broad rout. Of 2,700 listed names, 796 advanced and 1,641 declined (ADR proxy 48.5, average change −0.08%). The index damage came almost entirely from foreign selling in the semiconductor complex.
The defining flow: foreigners sold SK Hynix (000660.KS) for a net −1.08 trillion won — the single largest visible outflow in the snapshot. Samsung Electronics (005930.KS, −4.05%), Samsung Electronics preferred (005935.KS, −5.12%), SK Square (402340.KS, −8.17%), and Hanmi Semiconductor (042700.KS, −2.60%) compounded the damage. The catalyst is a rate-and-cost-of-capital double squeeze: US 10-year yield reached 4.97% (+0.19pp in five days) while Brent jumped 6.2% to $107.5 — both discount-rate and margin headwinds for growth-heavy names.
Program pressure amplified the move. KOSPI futures basis compressed to −2.43, market program selling reached −2.73 trillion won (non-arbitrage −2.71 trillion), and ETF net creation turned −179.7 billion won. The passive unwind explains much of KOSPI’s underperformance versus KOSDAQ.
Institutions rotated into industrials and selected cyclicals. HD Korea Shipbuilding (009540.KS), HD Heavy Industries (329180.KS), and LG Energy Solution (373220.KS) attracted institutional net buying. Samsung Electro-Mechanics (009150.KS, −4.5%) and Fadu (440110.KS, −11.24%) showed a foreign/institutional split — foreigners sold while institutions stepped in, a divergence that merits watching for mean-reversion setups.
Selective healthcare demand persisted. Pharma Research (214450.KS, +1.02%) and Celltrion (068270.KS, +0.34%) logged foreign net buying against the tape. DB Hitek (000990.KS) rallied +5.20% on strong volume.
Bottom line: the KR Bear call is intact and well-supported by derivatives, passive flows, and the macro backdrop. The tactical opportunity is in mid-cap quality compounders where earnings leverage is being independently re-priced — the screener output below is the best current map of where that thesis is holding.
Today’s Quality Re-Rating Candidates
Source: KR Meta Screener + Screener Intersection Summary (Sep 14, 2026). Universe: 157 tickers scored. Screener abbreviations: QC = Quality Compounder; CR = Cycle Rerating; SMQ = Smart Money Quality; SME = Smart Money Earnings; PEAD = Post-Earnings Drift.
Today’s meta screener produced a K-Beauty OEM cluster sitting alongside a power-equipment compounder and a pharma holding company. SamcNS is the only name hitting four independent screener axes — the strongest multi-evidence setup in today’s run. Candidates with 3+ screener overlaps should usually lead; the Meta Screener order is preferred here because it weighs DART official catalysts and evidence-family independence beyond raw overlap count.
| # | Ticker | Name | Meta Score | Overlap | Screeners | Key Metrics | DART Catalyst |
|---|---|---|---|---|---|---|---|
| 1 | 252990.KQ | SamcNS | 61.2 | 4 | QC, CR, SME, PEAD | ROE 9.7%, OP +182.7%, Margin +9.1pp | IR event Sep 7 |
| 2 | 008930.KS | Hanmi Science | 56.5 | 2 | QC, CR | ROE 12.3%, OP +40.3%, Margin +2.5pp | AML drug licensing deal |
| 3 | 119850.KQ | GNC Energy | 53.0 | 2 | QC, PEAD | ROE 21.1%, OP +55.8%, Margin +4.8pp | Supply contract Sep 11 |
| 4 | 161890.KS | Kolmar Korea | 51.1 | 2 | QC, PEAD | ROE 14.7%, OP +23.6%, Foreign 40.9% | 7 DART catalysts, IR blitz |
| 5 | 003350.KS | Korea Cosmetics Mfg | 50.9 | 3 | SMQ, CR, SME | ROE 30.6%, OP +24.2%, Margin +2.0pp | Retail supply absorbed |
| 6 | 241710.KQ | Cosméca Korea | 49.3 | 2 | QC, PEAD | ROE 19.3%, OP +38.2%, Margin +1.5pp | IR + merger filing |
| 7 | 072950.KQ | Bitsem Electronics | 38.2 | 3 | SMQ, CR, SME | OP +76.5%, Margin +1.5pp, Rev +42.1% | No filings |
| 8 | 425420.KQ | TFI | 37.3 | 3 | SMQ, CR, SME | OP +334.0%, Margin +11.1pp, Rev +51.8% | 1 DART catalyst |
Top 3 Context
#1 — SamcNS (252990.KQ) | Electronic Components
SamcNS manufactures high-precision electronic components. It is today’s sole four-screener name — Quality Compounder, Cycle Rerating, Smart Money Earnings, and PEAD — making it the most evidence-dense candidate in the run. Revenue grew 46.3% YoY while operating profit expanded 182.7%, lifting the operating margin to 18.8% (+9.1pp): a textbook operating-leverage re-pricing setup. RS percentile sits at 97–98 across all four screeners, and the stock closed at its 52-week high with positive foreign flow (Kiwoom surface: foreign rank #349, foreign flow +). The Sep 7 IR event is an additional catalyst layer. Next check: whether the margin expansion is structural (product mix or pricing power) or project-timing driven, and whether the current revenue run-rate supports sustained 18%+ margins.
#2 — Hanmi Science (008930.KS) | Pharma Holding
Hanmi Science is the controlling shareholder of Hanmi Pharmaceutical. It clears Quality Compounder (ROE 12.3%, OP +40.3%, Margin +2.5pp) and Cycle Rerating screens, and carries a hard DART catalyst: a disclosed licensing deal for HM43239, an AML (acute myeloid leukemia) treatment, representing a binary event not yet fully priced into the five-day flow picture. Note the caution: Kiwoom surface shows foreign and quality-institutional flow negative over five days, with 4.4% short interest. The meta rank holds at #2 because the official catalyst lifts the evidence score beyond what the flow signal alone would suggest. Next check: deal economics (upfront versus milestone split) and whether licensing income recognition creates a near-term earnings revision trigger.
#3 — GNC Energy (119850.KQ) | Power Equipment
GNC Energy designs transformers and power conversion systems for industrial and renewable energy clients. Quality Compounder passage is clean: ROE 21.1%, OP +55.8%, margin +4.8pp. A DART-confirmed supply contract filed Sep 11 adds the official catalyst layer. The PEAD signal is Tier A but composite score −0.72 (Kiwoom surface drag from short-term lending activity), meaning post-earnings drift has not yet cleanly materialized — the setup is early-stage. Quality-institutional flow is positive (Kiwoom rank #277, qualified institution buying confirmed). Next check: contract size relative to trailing revenue run-rate and order-book visibility into 2027.
K-Beauty OEM Watch
Kolmar Korea (161890.KS), Korea Cosmetics Mfg (003350.KS), and Cosméca Korea (241710.KQ) all land in today’s top-6 meta candidates — an unusual cluster concentration. All three are contract cosmetics manufacturers serving Korean and global beauty brands. Kolmar ran a seven-filing DART IR blitz this week, signaling active investor engagement. Korea Cosmetics Mfg has the most active flow signal: retail sellers (−39.4 billion won over five days) are being absorbed by foreign and quality-institutional buyers (+55.6 billion won net), with 20-day momentum at +29.9% — the market is actively re-pricing the story. For Cosméca Korea (241710.KQ), a merger filing (DART Sep 11) alongside the PEAD signal introduces event-driven optionality. Any investor building a Korea mid-cap quality-compounder screen should treat this cluster as a single thematic check rather than three isolated names.
All data sourced from Research OS local DB as of Sep 14, 2026. DART filings cited are from Korea’s official disclosure system (dart.fss.or.kr). Ticker suffixes: .KS = KOSPI, .KQ = KOSDAQ. All screener signals are research candidates for further due diligence, not buy or sell recommendations.